Endothelial cell seeding of native vascular surfaces  by Walluscheck, Knut P. et al.
Eur J Vasc Endovasc Surg 11, 290-303 (1996) 
REVIEW ARTICLE 
Endothelial Cell Seeding of Native Vascular Surfaces 
Knut P. Walluscheck,* Gustav Steinhoff and Axel Haverich 
Department of Cardiovascular Surgery, University of Kiet, Germany. 
Key Words: Endothelial cells, -function, -injury, -seeding; Heart valves; Vessels; Gene transf r; Transplantation. 
Introduction Coagulation 
In 1968, Mansfield et al. 1 developed the idea of lining 
prosthetic vascular grafts with cultured endothelial 
cells (EC) to decrease arly graft failure. Herring et al. 2 
revived this concept in 1978. Following modifications 
in culture techniques, large numbers of EC were 
available and so called "in vitro lining" and "micro- 
vascular seeding" was performed. In recent years, 
several investigators have shown the efficacy of these 
techniques in different animal models and for clinical 
application. While EC seeding of prosthetic vascular 
grafts has been performed for many years, first studies 
of endothelial cell seeding of de-endothelialised native 
arteries began in 1985. 3 This was the first step on a 
path potentially leading to essential innovations in 
vascular and transplant surgery. 
One of the main tasks of the intima is to keep a balance 
of local anticoagulation and haemostasis. To execute 
its anticoagulatory properties, the endothelium has to 
be able to synthesise a number of active substances 5 
such as prostacyclin, 6-8'21-25 endothelium-derived 
relaxing factor (EDRF), 9'26-28 tissue-type plasminogen 
activator (t-PA) and 13-hydroxy-9, 11-octadecadienoic 
acid (13-HODE)J ° Procoagulant factors are released 
by EC under certain pathological circumstances, such 
as mechanical or chemical trauma. These factors 
would include von Willebrand Factor (vWF), 11-15 t-PA 
Endothelial Cell Function 
The vascular endothelium exists as a monolayer of 
flattened cells which constitutes the entire intima (Fig. 
1). Its physiological properties include pro- and 
anticoagulatory effects, acting as a physical and 
permeability barrier, and its interaction with corpus- 
cular blood elements and cells of the vessel wall. 4 
*Please address all correspondence to: Knut Peer Walluscheck, 
Klinik ffir Herz- u. Gef~gchirurgie, Christian-Albrechts-Universitfit 
Kiel, Arnold-Heller Str. 7, 24105 Kiel, Germany. 
Fig. 1. Scanning electron micrograph of human venous endothelial 
cells grown in cell culture on a glass cover slip. Typical morpho- 
logical appearance of preconfluent flattened cells with beginning 
marginal overlapping and microvilli. The scale bar represents 
20 ~tm. 
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inhibitors, 16 tissue factor, 4'17 collagen 18'19 and 
fibronectin. 13,2° 
Overall, a complexity of systems is involved in the 
anticoagulant function of the endothelium. Any 
pathological disturbance of the balance of this reg- 
ulatory system may result in increased thromboge- 
nicity of either vascular grafts or native vessels. 
Permeability barrier 
The second main function of the endothelium repre- 
sents its barrier function, controlling the movement of 
plasma proteines into the subendothelial interstitium. 
Several humoral mediators promote transendothelial 
transport of macromolecules by different mechanisms 
e.g. passage through cell junctions, 29 pinocytosis and 
endocytosis. 3°,31 
Cell-cell and cell-matrix interaction 
A further important endothelial cell characteristic is 
the ability to interact with other cells. EC are especially 
important for the control of the extravasation of 
immune-competent cells and tumour cells. In addition 
to lymphocytes and tumour cells, interaction with 
monocytes and polymorphonuclear leukocytes has 
32 been demonstrated. By recognition of specific recep- 
tors on the EC surface and subsequent cell adhesion to 
the endothelium, these cells may migrate into the 
subendothelial space. This effect can be part of an 
inflammatory esponse or the alloreactive response in 
organ transplantation. 4'33 The process of transendo- 
thelial migration has been subdivided into three steps: 
cell-recognition, cell-binding and migration. 34 Multi- 
ple interactions of cell adhesion molecules like 
VCAM-1, PECAM-1, L-selectins and integrins, and 
their receptors have recently been shown to be 
involved in adhesion 35-38 or selective migration 39 of 
circulating cells into the tissue. 
The endothelium represents the interface between 
an allograft or xenograft and the recipient's circulating 
immune system and therefore plays an important role 
in all phases of graft rejection after organ transplanta- 
tion. The expression of endothelial leukocyte adhesion 
molecule-1 (ELAM-1) as well as granule membrane 
protein-140 (GMP-140), increased activity of tissue 
factor, increased secretion of plasminogen activator 
inhibitor or decreased secretion of thrombomodulin, 
may lead to acute rejection. 4°Induction of an antigen- 
presenting function by EC of transplanted organs can 
cause acute cellular ejection or transplant-associated 
arteriopathy. Major histocompatibility complex 
(MHC) expression in cultured EC could be increased 
by interferon-gamma. Therefore, cytokines, released 
during an inflammatory process, may induce expres- 
sion of MHC class II antigens resulting in increased 
antigenicity. 41 This desirable feature of EC in the 
physiologic inflammatory response such as viral 
infection may be harmful in transplantation. Recently 
acquired knowledge about EC and its role in allor- 
eactivity may result in experiments aiming at the 
establishment of an immunocompliant endothelium 
in organ transplantation. 
The potential of EC for cell-matrix interaction has a 
decisive influence on the regenerative process after 
endothelial injury and the result of re-endothelialisa- 
tion by seeding. The EC is able to synthesise various 
matrix proteins forming the basement membrane. 
Further it initiates attachment by special receptors 
located on the cellular surface. The endothelial base- 
ment membrane has been shown to consist mainly of 
collagen IV, entactin, a heparan sulfate proteoglycan, 
laminin and fibronectin. 42 Cell surface receptors 
mediating EC attachment, migration, differentiation 
or growth arise from the integrin family and immuno- 
globulin superfamily of adhesion molecules (Fig. 2, 
Table 1).43'44 Specific integrin receptors were shown to 
recognise the RGD- (Arg-Gly-Asp) amino acid 
45-47 sequence in their ligand molecules. These recent 
advancements in the molecular understanding of cell- 
matrix interactions may be required to improve EC 
seeding and repair of vascular injury. 
Endothelial Injury 
Endothelial injury can easily be caused by mechanical 
disruption of the monolayer integrity, a well known 
mechanism occurring during surgical interventions or
percutanous transluminal angioplasty (PTA). Func- 
tional cell damage is also possible by infusion of 
solutions of non-physiologic composition (e.g. cardi- 
oplegic solution or contrast media), hypothermia, or 
ischaemia. 
Surgical intervention 
The prototype of surgical intervention using mechan- 
ical endothelial injury is the arterial thromboendarter- 
ectomy (TEA), as commonly performed in carotid, 
iliac or femoral arteries. An arteriotomy including 
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Fig. 2. Cell-membrane receptor interaction in EC seeding. Initiation of EC-EC-interaction in EC seeding process is mediated by PECAM-1 
adhesion molecules? 7 A definite cell-matrix adhesion is mainly constituted by interaction of matrix proteines, as fibronectin (FN), collagen 
(Coll), laminin (LN) or vitronectin (VN), with beta 1- and beta 3-integrins. 44 
Table 1. Adhesion molecules involved in EC attachment. 61- and 
f~3-integrins are mainly responsible for EC attachment o different 
proteins of extracellular matrix (ECM) 44 
Molecule Ligand Function 
Integrins 
alfil 
a2~1 
a3~1 
a4~1 
a5~1 
a6~1 
aVe1 
aV/33 
Collagen, Laminin 
Collagen, Laminin 
Fibronectin, Entactin, Coll., 
Lam. 
Fibronectin 
Fibronectin 
Laminin 
Vitronectin, Fibronectin, 
Collagen I 
Vitronectin, Fibronecthl, 
Collagen 
IG Supergene 
PECAM-1 PECAM-1 
attachment to ECM 
attachment to ECM 
attachment to ECM 
attachment to ECM 
attachment to ECM 
attachment to ECM 
attachment to ECM 
attachment to ECM 
initiation of EC-EC 
interation 
release. 5°'51 Distension of veins at high pressures 
during preparation results in even more severe endo- 
thelial damage. Therefore, distension at pressures 
above 100mm Hg should be avoided. 52 Use of the 
saphenous vein as an in situ arterial conduit for lower 
extremity revascularisation will allow for better endo- 
thelial preservation compared to reversed vein 
grafts, ~3 amplifying the importance of surgical han- 
dling on EC damage. The technique of storage before 
grafting has also been shown to be important for 
preservation of venous EC. As such, EC function was 
superior when stored in cold blood compared with 
crystalloid solutions. 52 
Percutanous transluminal angioplasty 
removal of an atherosclerotic plaque will definitely 
result in local, but complete de-endothelialisation f 
the vessel. 4s 
The technique of harvesting the saphenous vein for 
aortocoronary bypass grafting or reconstruction of 
peripheral arteries also affects endothelial integrity 
and subsequent graft patency and function. 49 After 
routine preparation endothelial coverage was 
reported to be reduced to about 30-45% by surgical 
handling alone. These findings were associated with a 
significant decline in EDRF and prostacyclin 
Percutaneous transluminal angioplasty of peripheral 
(PTA) or coronary arteries (PTCA) has been in clinical 
use for a long time. Early thrombotic reocclusion and 
late restenosis represents the major clinical problems 
of these interventions. 54 After successful PTCA, 
30-40% of the patients will suffer from restenosis 
within 3-6 months. 55-s7 
PTA in patients with femoropopliteal stenoses 
results in a 3-year patency rate of 68% for single short 
stenoses and of 20% for long and multiple stenoses. 58
De-endothelialisation f the vessel following PTA is 
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thought to be one of the main reasons for the 
development of intimal hyperplasia nd subsequent 
restenosis. 59-61 
Numerous reports of catheter-induced arterial dam- 
age have appeared in the literature on experimental 
vessel injury. 62-65 Several animal studies investigated 
the influence of balloon catheter techniques on the 
extent of mechanically induced endothelial injury, 
mostly by the use of a partially inflated Fogarty 
embolectomy catheter. Different models of arterial 
injury have been developed 59'66'67'69 and may be used 
to study effects of EC regeneration or seeding tech- 
niques. To evaluate the character of injury caused by 
balloon catheters, a defined level of shear force was 
applied to the carotid and femoral arteries of dogs. It 
was shown that forces of 30 g caused nearly no injurN 
60 g removed the endothelium by 50%, forces of 90 
and 120 g completely stripped the endothelium with- 
out injury of the media, and 200 g force caused intimal 
injury and fracturing of the internal elastic lamina. 
Usual embolectomy manoeuvres were found to 
require shear forces of about 60 g.68 
Cardioplegia and ischaemia 
Crystalloid hypercalaemic cardioplegic solutions are 
known to cause significant arterial endothelial cell 
damage compared with blood cardioplegia. Even 
fracture of the internal elastic lamina and marked 
fibrin and platelet deposition have been described. 7°A 
reversible loss of vasomotory properties, expressed by 
decreased relaxation after exposure to agonists releas- 
ing relaxing factors from the endothelium was 
observed by perfusion of porcine coronary arteries 
with crystalloid cardioplegia. 7~'72 Differences between 
various organ preservation fluids regarding their 
effect on endothelial function 73"74 and integrity 78 have 
also been reported. Bretschneider's cardioplegic solu- 
tion was shown to cause less EC damage than 
heparinised blood during a 2h storage period of 
human saphenous veins and bovine internal mam- 
mary arteries. 76 Furthermore, EC injury can occur as a 
result of ischaemia nd reperfusion. 77'17° Tsao et al. 78 
observed a progressive defect in endothelium- 
dependent vasorelaxation within 2.5 min of reperfu- 
sion using a coronary artery model in the cat. 
Endothelial cell dysfunction does occur before the 
development of myocardial cell damage and is sup- 
posed to result from oxygen free radicals, inactivating 
the release of endothelium-derived relaxing factor. 
Both ischaemia and exposure to hyperoxia may 
damage EC function. Grant et at. 79 found that high 
levels of inspired oxygen in premature infants and 
adults with lung injuries affects proliferation of EC by 
inactivation of essential growth factors. 
Endothelial Regeneration 
Complete or partial removal of the vascular endothe- 
lium can cause a variety of dysfunctions rendering fast 
endothelial regeneration desirable. The time course 
and extent of re-endothelialisation depends on differ- 
ent factors. Firstly, there are species-depending differ- 
ences. Following balloon de-endothelialisation f the 
carotid artery in rats and rabbits, Reidy et aL so showed 
that endothelial regrowth ceased after 2 weeks in 
rabbits and after 6 weeks in rats. In both species, large 
areas of vascular surface remained without endothe- 
lium. SecondlN the extent of de-endothelialisation 
does influence ndothelial regeneration and the occur- 
rence of intimal proliferation. 8~'82 Regrowth of an 
endothelial monolayer probably develops from areas 
of intact endothelium, usually from the border lines of 
the denuded vessel segment or from intact side 
branches of the affected vessel. Depending on the 
number of side branches of a particular vessel, the 
speed of re-endothelialisation may vary. 61 Influenced 
by factors previously described, investigators have 
disclosed different emporal results of EC regrowth. 
Using an arterial injury model in the rat Fishman et 
al. 59 found the common carotid artery to appear 
normally endothelialised 1 month after de-endothe- 
lialisation. Clowes et al., 83 by use of a different 
denudation technique, demonstrated that the endo- 
thelial ayer had still not fully regenerated I year after 
injury. Weidinger et al. 66 reported apersistent dysfunc- 
tion of regenerated endothelium after de-endothelial- 
isation of the rabbit iliac artery. Therefore, degree and 
duration of endothelial dysfunction, as measured by 
the endothelium-dependent relaxation of the vessel, 
appears to depend not only on the type but also on the 
severity of the injury. 
Endothelial Cell Seeding 
Being aware of the important role the vascular 
endothelium plays in a variety of organ systems and 
the time course and extent of its physiological regen- 
eration, early restitution of an intact endothelium after 
injury remains an understandable goal. Following 
early attempts to isolate and culture non-human EC in 
1922, 84 several investigators developed advanced cul- 
ture techniques for human umbilical vein EC, 85 adult 
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human venous EC 86"87 and human microvascular EC 
from different sources. 88-91 By use of these techniques 
larger numbers of EC could be prepared. 
The first substrate for endothelial cell seeding were 
artificial vascular prostheses because physiological EC 
ingrowth is limited to a short distance from each 
anastomosis n humans. 92 Initial attempts of seeding 
vascular prostheses in animals were performed in 
1975, 93 and in 1978 Herring et al. 94 reported a single- 
staged technique for experimental EC seeding. These 
seeding techniques suffered from the problem of a 
relatively low number of available cells when using 
adult venous EC. Microvascular cells derived from 
omental tissue, by contrast, provided sufficient num- 
bers of cells for seeding, but were of mesothelial 
origin. 95-97 For these reasons, two-staged seeding 
techniques were developed, where the low primary 
yield of adult venous EC was multiplicated by tissue 
culture prior to seeding. 98"99 
Because of the reduced adhesion of EC to artificial 
surfaces, a number of investigations was performed to 
increase attachment on various prosthetic materials 
and precoating substances. Synthetic graft materials 
such as Dacron, 1°°-1°6 Teflon, 1°7 polyurethane 1°8'1°9 
(Fig. 3) and particularly polytetrafluoroethylene 
(PTFE) 99'u°'111 were used. To improve EC attachment 
and retention on artificial surfaces precoating tech- 
niques using coagulated blood, 94 human serum, 112 
naturally produced extracellular matrix, 113 collagen, 114 
125 226 224 217 220 laminin, transglutinine, fibronectin ' - and 
fibrin glue 121-123 were used. All these methods were 
able to increase EC attachment, but several problems 
of EC seeding of artificial surfaces remained unsolved. 
As such, the difficulty in providing a suitable matrix 
for durable EC adhesion on different artificial materi- 
als was encountered. Recent studies have demon- 
strated that the arginine-glycine-aspartic ac d (RGD) 
sequence of many extracellular matrix proteins inter- 
acts with the integrin family of cell-matrix receptors 
on EC, which is known to be the major functional 
receptor of cell attachment to matrix pro- 
teins. 46'47"124-126 While Sank et al. 127 could not enhance 
EC adhesion to PTFE vascular grafts by simply 
preincubating the prostheses with synthetic RGD- 
peptides compared with fibronectin coated prostheses, 
our group has developed a new technique of coupling 
the ePTFE graft surface with EC adhesion promoting 
RGD-containing synthetic peptides and achieved a 
significantly higher EC attachment (Fig. 4). This 
method is both easily applicable and absolutely sterile 
and may open new perspectives in seeding various 
artificial materials and native surfaces. After initial 
disappointment in human clinical trials 121'~aa 
improvements in cell culture, precoating technology 
and seeding technique have r sulted in enhanced 
patency rates of seeded vascular grafts in peripheral 
vascular bypass surgery. 122'129 In 1994, Zilla et al. 123 
r ported a superior 3-year patency rate (32 month) of 
84.7% after implantation of femoropopliteal bypass 
grafts using endothelialised ePTFE prostheses com- 
pared with 55.4% in untreated grafts. Artificial vas- 
cular prostheses, however, are not the only subject for 
potential application f endothelial cell seeding. In 
particular, native vascular surfaces may provide 
ample opportunity to benefit from this evolving 
technique. 
Fig. 3. Gelatine-coated polyurethane vascular graft after 30min of 
seeding with adult human venous endothelial cells and 60 min of 
perfusion in an artificial flow circuit. The scanning electron 
microscopy shows the fast establishment of a preconfluent EClining 
and tight cell attachment despite previous high flow perfusion of 
100 ml/min. The scale bar represents 50/~m. 
Arterial vessels 
Endarterectomy of atherosclerotic and stenotic arteries 
is a common surgical technique. The resulting injury 
of the arterial wall and its endothelium is known to 
leave behind a thrombogenic surface attracting cor- 
puscular blood elements and plasmatic coagulation 
factors. Lusby et al. 48 investigated platelet deposition 
after carotid endarterectomy in a canine model by 
labeling autologous platelets with indium-Ill. Com- 
pared with untreated control vessels, where no plate- 
let deposition was detected, the endarterectomised 
arteries howed immediate platelet deposition reach- 
ing a maximum i h after EC injury. Although different 
pharmacological 13°'131 and mechanical methods 132 
could lower the incidence of thrombo-occlusive events 
after endothelial injur> the immediate restitution of a 
physiologically functionally intact and therefore 
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(c} 
Fig. 4. Scanning electron micrograph of an expanded polytetra- 
fluoroethylene (ePTFE) vascular graft (a) uncoated (b) fibronectin 
coated or (c) treated with an adhesion promoting RGD-peptide. 
Specimens were taken after 30 rain of human venous EC seeding 
and application fshear stress in an artificial f ow circuit for 60 rain. 
EC adhesion on RGD-treated grafts was significantly increased 
(30.6% + 2.1%/19.3% + 2.8%) compared with uncoated 
(14.9% _+ 3.1%/2.0% + 1.0%) and fibronectin coated grafts 
(26.0% + 3.3%/11.8% _+1.6%). The scale bar represents 20~m. 
antithrombotic vascular intima seems to be the opti- 
mal solution. 
In 1985, Bush et al. 3 first examined the role of 
autologous EC seeding for luminal healing of arterial 
endarterectomy sites. In their stud)~ mongrel dogs 
underwent segmental bilateral carotid endarterect- 
omy. While one side was inoculated with cultured 
autologous venous EC for lh,  the contralateral side 
was only sham-seeded. At 2 weeks, scanning electron 
microscopy showed an excellent' luminal coverage 
with endothelial-like c lls in the seeded arteries while 
sham-seeded vessels showed only minimal luminal 
healing. Furthermore, prostacyclin production in 
seeded arteries was similar to that in normal host 
arteries. In sham-seeded arteries, prostacyclin produc- 
tion was significantly decreased. Accordingly, Bush et 
al. in their animal model demonstrated re-endothelial- 
isation of denuded vascular sites after surgery to be 
feasible. But would it be possible to decrease thrombo- 
genicity or neointimal hyperplasia and increase 
patency rates by EC seeding techniques? Comparing 
EC seeding with antiplatelet therapy using aspirin, 
Bush et al. 13s found a patency rate of 88% in the treated 
and 35% in the untreated arteries at 6 weeks. Fur- 
thermore, there was significant inhibition of neointi- 
mal hyperplasia in the EC seeded arteries compared 
with both untreated vessels and after aspirin treat- 
ment alone. 
Despite these tudies demonstrating the benefits of 
EC seeding after surgical endarterectomy, many ques- 
tions remained to be answered before clinical applica- 
tion appeared possible. EC attachment characteristics, 
the durability of the seeded cells under blood flow 
conditions and their capability to produce thrombore- 
sistance to vascular surfaces immediately after surgi- 
cal intervention had to be further investigated. 
Schneider et al. TM used a baboon model where they 
firstly applied EC seeding of cultured arterial cells to 
segments of the endarterectomised aorta in vitro. They 
then inserted the vessels either in an artificial perfu- 
sion circuit or an in vivo exteriorised femoral AV- 
shunt. Eighty percent of the seeded and confluently 
spreaded EC were retained after lh  of exposure to 
artificial high flOW conditions, maintaining a confluent 
endothelial monolayer. Even in arterial segments, 
acutely seeded and without spreading EC, a confluent 
monolayer was formed after I h of perfusion. Throm- 
bus formation, as measured by deposition of labeled 
platelets, was assessed after placement of vascular 
segments in the AV-shunt for i h. Platelet deposition 
on endarterectomised arteries was significantly 
decreased on EC seeded segments compared with 
unseeded segments, while platelet deposition on non- 
endarterectomised arteries was negligible. 
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Platelet deposition was also assessed in a canine 
animal model by Sterpetti et al. 135 while observing a
longer postoperative period. After bilateral carotid 
endarterectomy and unilateral seeding with labelled 
autologous venous EC, platelet uptake was sig- 
nificantly reduced on the seeded side compared with 
unseeded arteries even 4 weeks after surgery. Never- 
theless, scanning electron microscopy performed after 
explantation of seeded carotid arteries detected 
remaining non-endothelialised areas covered with a 
layer of platelets, fibrin and leukocytes. To achieve 
optimal thromboresistance of seeded vascular sur- 
faces, it was felt that such denuded areas should be 
avoided or at least reduced in size. For this purpose it 
was important o investigate the extension of luminal 
EC coverage in seeded and unseeded arteries follow- 
ing de-endothelialisation. 
In 1992, Sawchuk et al. 136 performed an investiga- 
tion addressing this question. Cultured autologous 
venous EC were seeded on canine carotid arteries 
following argon laser endarterectomy. The percentage 
of luminal surface covered with EC was evaluated by 
scanning electron microscopy and by planimetry at I h 
and at 24h after seeding. Seeded arteries demon- 
strated 35% EC coverage after l h and 58% EC 
coverage after 24 h, whereas there was no EC coverage 
apparent on unseeded arteries. 
Schneider et al. 134 demonstrated that immediate 
thromboresistance after surgical endarterectomy is 
achievable by short-time EC seeding. Bush et al. 3 
showed a confluent endothelial monolayer 2 weeks 
after EC seeding. But are the cells detectable ong-term 
identical to those initially placed on the vascular 
surface?. Dailey et al. t37 developed an intravital 
fluorescent staining technique for labeling EC. They 
then seeded EC in de-endothelialised segments of rat 
abdominal aortas. Five days later, EC on previously 
denuded areas, as recognised by scanning electron 
microscop~ were shown to contain fluorescent dye, 
therefore representing the originally seeded cells. This 
technique, however, has limited application for long- 
term studies, because of the cellular loss of fluores- 
cence and potential changes of EC viability and 
attachment. Other methods, such as genetic transfer of 
a recombinant marker protein could be applicable for 
this purpose. Genetic modification of EC prior to 
seeding may also be used in the future to produce 
substrates of therapeutic value, and a potential design 
138 171 173 175 of future drug delivery systems. ' ' ' 
~39 In 1989, Nabel et al. described a technique for EC 
seeding and subsequent endothelial expression of 
recombinant genes in vivo. Cultured venous EC from 
syngeneic minipigs were infected with a ~-galactosi- 
dase-transducing retroviral vector. After balloon cath- 
eter denudation of the iliofemoral arteries genetically 
altered EC were incubated with the luminal surface by 
means of a double-balloon catheter for 30 min. These 
arterial segments were explanted 2 to 4 weeks later 
and ~-galactosidase activity was demonstrated by 
indicator staining, while seeded but uninfected EC 
exhibited no staining. In contrast to this study Conte et 
al. ~4° investigated the repopulation of denuded arter- 
ies with autologous genetically modified EC in a 
rabbit animal-model in 1994. This group used a high- 
titre virus instead of a low-titre virus, therefore 
avoiding prolonged cell culture before seeding. At 1 
week after seeding, staining showed 40-90% of the 
vessel surface to be covered with genetically modified 
cells. Additionall~ re-endothelialisation was assessed 
by scanning electron microscop~ demonstrating a 
confluent EC monolayer. These results were found 
after seeding in confluent as well as in subconfluent 
density. Conversel~ examination at 2 weeks after 
seeding showed a decrease in staining of genetically 
modified cells while the endothelial monolayer still 
remained intact. A definite explanation for this finding 
has not been found until now, but either a limited time 
span of vector-mediated protein expression or replace- 
ment of the transduced cells by EC of endogenous 
origin must be discussed. In any case, an early and 
persisting re-establishment of an endothelial mono- 
layer, mainly consisting of seeded cells, was proved. 
Genetic modification and subsequent EC seeding on 
native vessels, vascular prostheses or intravascular 
stents was shown to be able to provide an endothe- 
lium producing proteins such as ~-galactosidase, 139 
141 142 t-PA or growth hormones. 
As reported earlier, intraluminal catheter techniques 
may produce severe endothelial damage. Conse- 
quentl~ investigations of EC seeding techniques after 
catheter induced denudation of arterial sites have 
been performed recently. Thompson et al. 143 in 1992, 
after de-endothelialisation of rabbit iliac arteries by a 
balloon angioplasty catheter, used a method of trans- 
luminal seeding of angioplasty sites with EC using a 
double-balloon catheter as previously applied by 
Nabel et al. 139 This seeding catheter, containing a 
central instillation port between two isolation bal- 
loons, excluded an arterial segment from the circula- 
tion and allowed instillation of a defined volume of 
EC suspension. The contralateral arterial side was 
sham-seeded. Gamma activity of labelled EC was 
measured after 30 min of seeding for at least 100 min. 
Following EC incubation, 89% of the cells were 
retained. On restoration of blood flow a period of high 
cell loss ensued, leading to a plateau with minimal 
further cell loss and an ultimate cell retention of 
17%. 
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In continuation of their previous study on seeding 
angioplasty sites, Thompson et al. 144 assessed platelet 
deposition on EC seeded and unseeded sites in 1994. 
After bilateral de-endothelialisation and unilateral EC 
seeding of supraconfluent density, deposition of 
labelled autologous platelets on de-endothelialised 
but unseeded sites was significantly higher than on 
undamaged arterial segments. EC seeding after de- 
endothelialisation resulted in reduced platelet deposi- 
tion to an extent comparable with undamaged sites. 
The question remains, however, whether an early 
restoration of endothelial coverage would indeed 
reduce intimal hyperplasia. In 1995, Conte et al. 172 
concluded in a rabbit-model that EC seeding accel- 
erated the restoration of the endothelial monolayer 
but failed to attenuate intimal thickening. Never- 
theless, further investigations in other clinically rele- 
vant models should be performed. Also, clinical 
seeding trials to prevent early and late reocclusion 
after PTA have not yet been performed. Recently, in 
own experiments we found that rapid in vitro re- 
endothelialisation f denuded human carotid arteries 
by adult human venous EC is possible (Fig. 5). 
fixative. 155-157 Treatment of fixed heart valves using 
L-glutamic acid conversely resulted in regular EC 
proliferation in vitro. 158 Also, EC seeding of glutar- 
aldehyde-fixed human vein grafts after a detoxifying 
postfixation treatment was shown to be successful 
both in vitro and in vivo, and improved biocompatibil- 
ity was demonstrated, ls9 Leukauf et aI. ~6° compared in 
vitro EC seeding of glutaraldehyde-fixed and detox- 
ified bovine pericardium to spontanous EC ingrowth 
in vivo in an animal model. While seeded cells were 
only loosely bound to the underlying tissue, in vivo 
ingrowing cells demonstrated direct contact and sig- 
nificantly decreased thrombogenicity. Therefore, Leu- 
kauf et al. postulated in vivo EC ingrowth to be the 
most promising approach for further research. While 
Heart valves 
The first aortic valve allograft implantation was 
reported in 1962.145 Subsequent long-term experience 
has shown that the main disadvantages of these 
substitutes is similar to those previously demon- 
146 147 strated in preserved valve prostheses. ' Tissue 
degeneration of cardiac valve bioprostheses, pe- 
cially cuspal mineralisation, often makes reoperation 
necessary within 7 to 10 years. 14s Many studies have 
been performed to investigate the reasons for and time 
course of post~mplantation changes. The fixation 
process and immunological effects of remaining vital 
donor EC are thought to be responsible for the 
alterations described. 149-152. Therefore, the "ideal" 
biological valve is felt to be a graft lined with 
autologous endothelium and without release of toxins 
from the fixation process. 153 EC seeding of bio- 
prosthetic tissue appears to be a possible solution. In 
1988, Hoch et al. TM described the feasibility of in vitro 
endothelialisation of aldehyde-stabilised native ves- 
sels. After incubation for up to 120 min, immediate 
examination of EC coverage revealed large confluent 
areas of EC. Unfortunately, a longer follow-up was not 
obtained and subsequent cell loss could not be 
assessed. In other studies, EC lining of glutaralde- 
hyde-preserved bioprosthetic heart valves resulted in 
cell death due to the release of remaining toxic 
(b) 
Fig. 5. Human common carotid artery (a)after balloon-catheter d -
endothelialisation and (b) after 30 min of adult human venous EC 
seeding. Scanning electron microscopy shows complete removal of 
the endothelium after application ofa balloon-catheter and a high 
coverage of attached round or spreaded EC after seeding. The scale 
bar represents 20~tm. 
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spontaneous endothelialisation f bioprosthetic heart 
valves was not believed to Occur, 161 in 1995 Zavazava 
et al. 174 reported that porcine valves are re-endotheli- 
alised by human recipient endothelium in vivo. Never- 
theless, arapid confluent and uniform in vivo endothe- 
lialisation certainly does not occur, Different 
techniques ofpreservation have been evaluated in this 
respect. Eberl et al. ~55 compared EC seeding on fresh 
unpreserved human valve leaflets and after alter- 
native preservation as well as after routine preserva- 
tion in an in vitro investigation. On commonly 
preserved valve leaflets no viable EC could be 
detected 2 days after seeding. Conversely, on non- 
preserved as well as on specially preserved leaflets a 
persistent endothelial monolayer was established 
between days 6 and 10 after seeding. Therefore, 
specially adapted preservation techniques as well as 
specific postfixation treatment may be able to provide 
suitable conditions for re-endothelialisation f bio- 
prosthetic heart valves. 
Cryopreservation f human allografts followed by 
autologous EC seeding prior to implantation could be 
a further way to achieve the aim of an endothelial 
lined and non-toxic heart valve prosthesis. Gournier et 
al. 162 investigated the biomechanical properties and 
histological appearance of cryopreserved human arte- 
rial allografts. A programmed cryopreservation using 
15% dimethyl sulfoxide as cryoprotectant was 
applied. Compared with fresh arteries, there was no 
difference in mechanical and biochemical properties 
and ultrastructure. Partial EC coverage was detected, 
nevertheless there was no investigation ofEC viability 
and function. Yankah et al. 151 demonstrated a high rate 
of viable EC on cryopreserved human heart valve 
allografts that were also expressing surface antigen. 
Human heart valve endothelium was shown to have 
an immunogenic stimulatory effect in a mixed cell 
culture reaction two to three times higher than 
peripheral blood lymphocytes. 152 Remaining viable 
donor endothelium after transplantation of human 
allografts is supposed to be destroyed by rejection. 
Accordingly, Lupinetti et al. 163 demonstrated a simul- 
taneous decrease of EC viability and immunogenicity 
in a rat model of valve allograft implantation. In 
contrast to previous described results, 151'152 this study 
did not confirm the expression of antigens on EC to be 
a reliable predictor of the immunological response. To 
further examine the consequences of histoincompati- 
bility and cryopreservation EC replication, Lupi- 
164 netti et al. performed both syngeneic and allogeneic 
transplantations of fresh and cryopreserved aortic 
valves in rats. They demonstrated that immunologic 
differences do not affect EC replication in the early 
postoperative period. However, cryopreservation 
leads to a non-replicating endothelium. 
Summarising these findings, the durable establish- 
ment of an autologous EC monolayer prior to trans- 
plantation of heart valve allografts or xenografts 
seems to be a promising technique for the preservation 
of graft degeneration and, possibly, thromboembolic 
events. Prior to autologous EC seeding, it appears 
reasonable tocompletely remove remaining donor EC. 
Loose et al. 16s developed a technique using desoxy- 
cholic acid for in vitro de-endothelialisation of rat heart 
valves, simultaneously preserving the basement mem- 
brane. This technique may provide a suitable matrix 
for subsequent EC seeding. Further investigations are 
felt to be necessary toassess possible inhibitory effects 
of this biological detergent on EC attachment, such as 
biochemical alterations in the ligand structures of 
cellular adhesion molecules. 
Attempts at EC seeding of intact heart valves in vitro 
are very rare. Bengtsson et at. 166 assessed re-endothe- 
lialisation of isolated cusps and intact detoxified 
commercially available porcine heart valves using 
human venous EC. A seeding device was designed to 
allow for an uniform seeding of intact valves. Under 
prolonged culture conditions, a confluent endothelial 
monolayer was detected on isolated cusps 7 days after 
seeding. Seeding of intact heart valve prostheses, by 
contrast, led to successful attachment and spreading 
of EC 1 day after seeding, but after 7 days only 
unspread and non-viable cells were observed. Not 
withstanding these disappointing results probably 
due to residual cell-toxic solution retained in the 
sewing ring or stent, it was shown that EC can be 
uniformly distributed on intact heart valve bio- 
prostheses. Further efforts to completely detoxify 
glutaraldehyde-treated bioprostheses, or further 
attempts to completely seed cryopreserved allo- or 
xenografts, can possibly provide biologically and 
immunologically fully compatible heart valve bio- 
prostheses in the near future. 
Outlook 
Previous clinical and experimental studies have 
clearly defined the vascular endothelium to be of 
utmost importance with respect to blood flow, coagu- 
lation, vasomotor properties, and immunogenicity. 
Defective ndothelium has been successfully replaced 
in experiments and added to the surfaces of prosthetic 
vascular grafts clinically. These investigations have 
resulted in a rapidly growing experience with respect 
to cell harvesting and cell culture techniques to 
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provide the requisite cell numbers. The basic applica- 
bility of these methods has opened new perspectives 
for further pre-clinical and clinical use including 
coronary and peripheral vascular surgery, transplanta- 
tion, heart valve replacement and pharmacology. 
A revival of seemingly outdated surgical tech- 
niques, such as endarterectomy of coronary arteries, 
appears to be conceivable in the light of the current 
progress and the potential of simultaneous EC seed- 
ing. Furthermore, EC seeding to line the inner vas- 
cular surface of complete organ systems with autolo- 
gous cells prior to transplantation may be investigated 
in pre-clinical experiments. As a barrier between the 
circulating blood of the host and the immunoreactive 
donor tissue the endothelium ay have significant 
influence on the process of allograft rejection. Replace- 
ment of the antigeneic endothelium of a transplant 
organ by autologous host endothelium may also 
prevent hyperacute r jection, known to be an impor- 
tant impediment in xenotransplantation. 167'177 In this 
context, Stevens et al. 168 have described the first 
encouraging results by reseeding arterial grafts in a 
gulinea pig to rat xenograft model. In 1995, Quigley et 
76 at. reported that random autologous EC seeding of 
a rodent heart allograft without removal of the donor 
endothelium facilitated long-term organ survival and 
significantly reduced the required immunosuppres- 
sive therapy. 
The long-term results of biologic heart vane 
replacement may also benefit from EC seeding. Early 
calcification of gtutaraldehyde-preserved bioprosth- 
eses can possibly be prevented by combining an 
approach of detoxification with autologous EC seed- 
ing. Graft failure of cryopreserved allografts also is 
supposed to be reducible by the formation of a 
complete host endothelial monolayer prior to 
implantation. 
Genetic modification of EC with the opportunity to 
line vascular surfaces with an endothelium expressing 
therapeutic proteins may open a new avenue in EC 
seeding. After EC damage, seeding of genetically 
altered EC could prevent vascular occlusion by the 
immediate restoration of a functional endothelium 
and by secretion of gene products such as antith- 
rombotic agents directly into the circulation. The 
application of this design of a drug delivery system is 
also conceivable in nonvascular systemic diseases 
calling for a durable drug release. 169 
Any of these applications will call for an enormous 
further improvement in both cell harvest for provid- 
ing the required cell number and progress in seeding 
techniques including in vivo cell-lining. Until now EC 
seeding has been possible only by virtually undis- 
turbed incubation of EC with the graft surface. Our 
group has recently shown that the fast re-establish- 
ment of a confluent endothelial monolayer is possible 
by flow-seeding of human arteries; a technique proba- 
bly of great value for complete organ seeding trials. 
Further eduction of EC incubation time will remain 
one of the most urgent demands for the clinical 
application of EC seeding. By continuous increase in 
our understanding of the importance of adhesion 
molecules for EC attachment, improvement of EC 
adhesion by promotion of cell-matrix receptors 
appears to be possible. 
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